{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:00:07Z","timestamp":1788814807322,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T00:00:00Z","timestamp":1514419200000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000124","name":"Office of Research on Women's Health","doi-asserted-by":"publisher","award":["K12 DA035150"],"award-info":[{"award-number":["K12 DA035150"]}],"id":[{"id":"10.13039\/100000124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12877-017-0690-2","type":"journal-article","created":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T01:25:12Z","timestamp":1514424312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["An investigation of factors predicting the type of bladder antimuscarinics initiated in Medicare nursing homes residents"],"prefix":"10.1186","volume":"17","author":[{"given":"Daniela C.","family":"Moga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qishan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie J.","family":"Goodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,28]]},"reference":[{"key":"690_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P, et al. The standardization of terminology of lower urinary function: report from the standardization sub-committee of the international continence society. Neurol Urodyn. 2002;21:167\u201378.","journal-title":"Neurol Urodyn"},{"issue":"2","key":"690_CR2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.18553\/jmcp.2014.20.2.130","volume":"20","author":"KS Coyne","year":"2014","unstructured":"Coyne KS, et al. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20(2):130\u201340.","journal-title":"J Manag Care Pharm"},{"issue":"4","key":"690_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/nau.20668","volume":"28","author":"MP Offermans","year":"2009","unstructured":"Offermans MP, et al. Prevalence of urinary incontinence and associated risk factors in nursing home residents: a systematic review. Neurourol Urodyn. 2009;28(4):288\u201394.","journal-title":"Neurourol Urodyn"},{"key":"690_CR4","first-page":"51","volume":"28","author":"S Charalambous","year":"2009","unstructured":"Charalambous S, Trantafylidis A. Impact of urinary incontinence on quality of life. Pelviperineology. 2009;28:51\u20135.","journal-title":"Pelviperineology"},{"issue":"5","key":"690_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/ageing\/26.5.367","volume":"26","author":"DH Thom","year":"1997","unstructured":"Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing. 1997;26(5):367\u201374.","journal-title":"Age Ageing"},{"issue":"9","key":"690_CR6","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1111\/j.1532-5415.2006.00861.x","volume":"54","author":"CE Dubeau","year":"2006","unstructured":"Dubeau CE, Simon SE, Morris JN. The effect of urinary incontinence on quality of life in older nursing home residents. J Am Geriatr Soc. 2006;54(9):1325\u201333.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"690_CR7","first-page":"398","volume":"98","author":"L Wilson","year":"2001","unstructured":"Wilson L, et al. Annual direct cost of urinary incontinence. Obstet Gynecol. 2001;98(3):398\u2013406.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"690_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.urology.2009.06.096","volume":"75","author":"ML Ganz","year":"2010","unstructured":"Ganz ML, et al. Economic costs of overactive bladder in the United States. Urology. 2010;75(3):526\u201332. 532.e1-18","journal-title":"Urology"},{"issue":"3 Suppl 1","key":"690_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.amjmed.2005.12.014","volume":"119","author":"N Erdem","year":"2006","unstructured":"Erdem N, Chu FM. Management of overactive bladder and urge urinary incontinence in the elderly patient. Am J Med. 2006;119(3 Suppl 1):29\u201336.","journal-title":"Am J Med"},{"issue":"6","key":"690_CR10","doi-asserted-by":"publisher","first-page":"438","DOI":"10.7326\/0003-4819-122-6-199503150-00007","volume":"122","author":"JG Ouslander","year":"1995","unstructured":"Ouslander JG, Schnelle JF. Incontinence in the nursing home. Ann Intern Med. 1995;122(6):438\u201349.","journal-title":"Ann Intern Med"},{"issue":"2","key":"690_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1001\/archfami.6.2.114","volume":"6","author":"S McFall","year":"1997","unstructured":"McFall S, et al. Evaluation and treatment of urinary incontinence. Report of a physician survey. Arch Fam Med. 1997;6(2):114\u20139.","journal-title":"Arch Fam Med"},{"issue":"5","key":"690_CR12","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","volume":"193","author":"EA Gormley","year":"2015","unstructured":"Gormley EA, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment. J Urol. 2015;193(5):1572\u201380.","journal-title":"J Urol"},{"issue":"2","key":"690_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.2010.1972","volume":"305","author":"PS Goode","year":"2011","unstructured":"Goode PS, et al. Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: a randomized controlled trial. JAMA. 2011;305(2):151\u20139.","journal-title":"JAMA"},{"issue":"5","key":"690_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJMoa0806375","volume":"360","author":"LL Subak","year":"2009","unstructured":"Subak LL, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009;360(5):481\u201390.","journal-title":"N Engl J Med"},{"issue":"6\u20137","key":"690_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0024-3205(98)00581-5","volume":"64","author":"SS Hegde","year":"1999","unstructured":"Hegde SS, Eglen RM. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci. 1999;64(6\u20137):419.","journal-title":"Life Sci"},{"issue":"5","key":"690_CR16","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/sj.bjp.0704781","volume":"136","author":"C Fetscher","year":"2002","unstructured":"Fetscher C, et al. M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol. 2002;136(5):641.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"690_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1525-8610(04)70206-6","volume":"2","author":"JG Ouslander","year":"2001","unstructured":"Ouslander JG, et al. Implementation of a nursing home urinary incontinence management program with and without tolterodine. J Am Med Dir Assoc. 2001;2(5):207\u201314.","journal-title":"J Am Med Dir Assoc"},{"issue":"5","key":"690_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s001929970003","volume":"10","author":"HP Drutz","year":"1999","unstructured":"Drutz HP, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 1999;10(5):283\u20139.","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"issue":"5","key":"690_CR19","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/S0022-5347(05)66326-4","volume":"165","author":"J Malone Lee","year":"2001","unstructured":"Malone Lee J, et al. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol. 2001;165(5):1452\u20136.","journal-title":"J Urol"},{"issue":"6","key":"690_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.4065\/78.6.687","volume":"78","author":"A Diokno","year":"2003","unstructured":"Diokno A, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78(6):687\u201395.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"690_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.amjopharm.2006.03.004","volume":"4","author":"A Wagg","year":"2006","unstructured":"Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother. 2006;4(1):14\u201324.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"10","key":"690_CR22","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1185\/03007X226294","volume":"23","author":"C Chapple","year":"2007","unstructured":"Chapple C, et al. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin. 2007;23(10):2347\u201358.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"690_CR23","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/j.1532-5415.2008.01680.x","volume":"56","author":"TE Lackner","year":"2008","unstructured":"Lackner TE, et al. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc. 2008;56(5):862\u201370.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"690_CR24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1474-8673.2006.00368.x","volume":"26","author":"RM Eglen","year":"2006","unstructured":"Eglen RM. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol. 2006;26(3):219.","journal-title":"Auton Autacoid Pharmacol"},{"issue":"8","key":"690_CR25","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/j.1368-5031.2005.00617.x","volume":"59","author":"F Haab","year":"2005","unstructured":"Haab F, Castro-Diaz D. Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract. 2005;59(8):931\u20137.","journal-title":"Int J Clin Pract"},{"issue":"11","key":"690_CR26","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1111\/j.1464-410X.2012.11023.x","volume":"110","author":"A Wagg","year":"2012","unstructured":"Wagg A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767\u201374.","journal-title":"BJU Int"},{"issue":"12","key":"690_CR27","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1111\/j.1532-5415.2005.00537.x","volume":"53","author":"G Kay","year":"2005","unstructured":"Kay G, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53(12):2195\u2013201.","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"690_CR28","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/archinternmed.2007.106","volume":"168","author":"J Rudolph","year":"2008","unstructured":"Rudolph J, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508\u201313.","journal-title":"Arch Intern Med"},{"issue":"2","key":"690_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.eururo.2006.03.060","volume":"50","author":"D De Ridder","year":"2006","unstructured":"De Ridder D. Antimuscarinics and cognitive function. Eur Urol. 2006;50(2):211\u20132.","journal-title":"Eur Urol"},{"issue":"2","key":"690_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jamda.2006.07.004","volume":"8","author":"S Narayanan","year":"2007","unstructured":"Narayanan S, et al. Is drug therapy for urinary incontinence used optimally in long-term care facilities? J Am Med Dir Assoc. 2007;8(2):98\u2013104.","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"690_CR31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.trci.2017.01.003","volume":"3","author":"DC Moga","year":"2017","unstructured":"Moga DC, et al. Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimers Dement (N Y). 2017;3(1):139\u201348.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"690_CR32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.eururo.2006.03.057","volume":"50","author":"G Kay","year":"2006","unstructured":"Kay G, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006;50(2):317.","journal-title":"Eur Urol"},{"issue":"4","key":"690_CR33","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/00019442-200504000-00009","volume":"13","author":"RD Jewart","year":"2005","unstructured":"Jewart RD, et al. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry. 2005;13(4):324\u20138.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"9","key":"690_CR34","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/j.1742-1241.2010.02449.x","volume":"64","author":"A Wagg","year":"2010","unstructured":"Wagg A, Verdejo C, Molander U. Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. Int J Clin Pract. 2010;64(9):1279\u201386.","journal-title":"Int J Clin Pract"},{"key":"690_CR35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/gps.2316","volume":"25","author":"B King-Kallimanis","year":"2010","unstructured":"King-Kallimanis B, et al. Longitudinal investigation of wandering behavior in department of veterans affairs nursing home care units. Int J Geriatr Psychiatry. 2010;25:166\u201374.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"10","key":"690_CR36","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jamda.2013.03.008","volume":"14","author":"D Moga","year":"2013","unstructured":"Moga D, et al. Risks and benefits of bladder antimuscarinics among elderly residents of veterans affairs community living centers. J Am Med Dir Assoc. 2013;14(10):749\u201360.","journal-title":"J Am Med Dir Assoc"},{"issue":"9","key":"690_CR37","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1046\/j.1464-410x.1999.00397.x","volume":"84","author":"KE Andersson","year":"1999","unstructured":"Andersson KE, et al. The pharmacological treatment of urinary incontinence. BJU Int. 1999;84(9):923\u201347.","journal-title":"BJU Int"},{"issue":"4","key":"690_CR38","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/MOU.0b013e32832ce8a4","volume":"19","author":"KE Andersson","year":"2009","unstructured":"Andersson KE, et al. Pharmacological treatment of overactive bladder: report from the international consultation on incontinence. Curr Opin Urol. 2009;19(4):380\u201394.","journal-title":"Curr Opin Urol"},{"issue":"2\u20133","key":"690_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0014-2999(98)00214-3","volume":"349","author":"PG Gillberg","year":"1998","unstructured":"Gillberg PG, Sundquist S, Nilvebrant L. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol. 1998;349(2\u20133):285\u201392.","journal-title":"Eur J Pharmacol"},{"issue":"Suppl 2","key":"690_CR40","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1038\/sj.bjp.0706560","volume":"147","author":"SS Hegde","year":"2006","unstructured":"Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol. 2006;147(Suppl 2):S80\u20137.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"690_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00210-002-0554-x","volume":"366","author":"K Ikeda","year":"2002","unstructured":"Ikeda K, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedeberg\u2019s Arch Pharmacol. 2002;366(2):97\u2013103.","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"6","key":"690_CR42","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11934-007-0046-0","volume":"8","author":"AP Klausner","year":"2007","unstructured":"Klausner AP, Steers WD. Antimuscarinics for the treatment of overactive bladder: a review of central nervous system effects. Curr Urol Rep. 2007;8(6):441\u20137.","journal-title":"Curr Urol Rep"},{"key":"690_CR43","first-page":"A445","volume":"21","author":"C Napier","year":"2002","unstructured":"Napier C, Gupta P. Darifenacin is selective for the human recombinant M3 receptor subtype [abstract]. Neurourol Urodyn. 2002;21:A445.","journal-title":"Neurourol Urodyn"},{"issue":"2\u20133","key":"690_CR44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0014-2999(97)89661-6","volume":"327","author":"L Nilvebrant","year":"1997","unstructured":"Nilvebrant L, et al. Tolterodine--a new bladder-selective antimuscarinic agent. Eur J Pharmacol. 1997;327(2\u20133):195\u2013207.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"690_CR45","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2165\/00002512-200522120-00003","volume":"22","author":"DR Staskin","year":"2005","unstructured":"Staskin DR. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging. 2005;22(12):1013\u201328.","journal-title":"Drugs Aging"},{"key":"690_CR46","doi-asserted-by":"publisher","first-page":"M174","DOI":"10.1093\/geronj\/49.4.M174","volume":"49","author":"J Morris","year":"1994","unstructured":"Morris J, et al. MDS Cognitive Performance Scale. J Gerontol. 1994;49:M174\u201382.","journal-title":"J Gerontol"},{"issue":"42","key":"690_CR47","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/j.1532-5415.1994.tb06984.x","volume":"1994","author":"S Hartmaier","year":"1994","unstructured":"Hartmaier S, et al. The MDS cognition scale: a valid instrument fo identifying and staging nursing home residents with dementia using the minimum data set. J Am Geriatr Soc. 1994;1994(42):1173\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"690_CR48","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1034\/j.1601-5215.2002.51017.x","volume":"51","author":"J Hirdes","year":"2003","unstructured":"Hirdes J, Frijters D, Teare G. The MDS-CHESS scale: a new measure to predict mortality in institutionalized older people. J Am Geriatr Soc. 2003;51(1):96\u2013100.","journal-title":"J Am Geriatr Soc"},{"key":"690_CR49","first-page":"61","volume":"14","author":"F Mahoney","year":"1965","unstructured":"Mahoney F, Barthel D. Functional evaluation: the Barthel index. MD State Med J. 1965;14:61\u20135.","journal-title":"MD State Med J"},{"issue":"1","key":"690_CR50","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8\u201327.","journal-title":"Med Care"},{"key":"690_CR51","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1177\/0091270006292126","volume":"46","author":"R Carnahan","year":"2006","unstructured":"Carnahan R, et al. The Anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481\u20136.","journal-title":"J Clin Pharmacol"},{"key":"690_CR52","unstructured":"SAS Institute Inc., SAS 9.4 Help and Documentation, Cary, NC: SAS Institute Inc.; 2013."},{"issue":"1","key":"690_CR53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JCP.0b013e31823f6f46","volume":"32","author":"K Huybrechts","year":"2012","unstructured":"Huybrechts K, et al. Variation in antipsychotic treatment choices across US nursing homes. J Clin Psychopharmacol. 2012;32(1):11\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"690_CR54","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1377\/hlthaff.26.5.1448","volume":"26","author":"DB Smith","year":"2007","unstructured":"Smith DB, Feng Z, Fennell ML, Zinn JS, Mor V. Separate and unequal: racial segregation and disparities in quality across US nursing homes. Health Aff. 2007;26(5):1448\u201358.","journal-title":"Health Aff"},{"issue":"5","key":"690_CR55","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1176\/appi.ps.52.5.666","volume":"52","author":"BL Svarstad","year":"2001","unstructured":"Svarstad BL, Mount JK, Bigelow W. Variations in the treatment culture of nursing homes and responses to regulations to reduce drug use. Psychiatr Serv. 2001;52(5):666\u201372.","journal-title":"Psychiatr Serv"},{"key":"690_CR56","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jamda.2007.08.005","volume":"9","author":"A Bharucha","year":"2008","unstructured":"Bharucha A, et al. Prevalence of behavioral symptoms: comparison of the minimum data set assessments with research instruments. J Am Med Dir Assoc. 2008;9:244\u201350.","journal-title":"J Am Med Dir Assoc"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-017-0690-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12877-017-0690-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-017-0690-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T11:00:13Z","timestamp":1660215613000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-017-0690-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["690"],"URL":"https:\/\/doi.org\/10.1186\/s12877-017-0690-2","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"18 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Study design and all of the analyses were conducted based on an a priori specified protocol approved by the Institutional Review Board at the University of Kentucky. Due to the retrospective nature of the design, the Institutional Review Board granted the investigators waiver of informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"295"}}